Suven Life Sciences has secured one product patent from Israel and one product patent from Japan corresponding to the New Chemical Entities for the treatment of disorders associated with Neurodegenerative diseases and patents are valid through 2036 and 2034 respectively. The granted claims of the patents include the class of selective M1 PAM and 5-HT4 … Read more
Suven Life Sciences (Suven) is participating and presenting positive Pre-clinical and Phase-1 clinical data of several advanced molecules from their portfolio of new chemical entities (NCEs) and the status of Phase 2 clinical trial of their lead compound SUVN-502 at Neuroscience 2018, organized by Society for Neuroscience being held at San Diego, USA during November … Read more
Suven Life Sciences is participating and presenting the baseline patient demographics and scales from the ongoing phase-2a proof-of-concept trial of SUVN-502 for moderate Alzheimer’s Disease at 11th clinical trials on Alzheimer’s disease (CTAD) during October 24-27, 2018 at Barcelona, Spain. SUVN-502 is a promising pure, 5-HT6 receptor antagonist in development for the treatment of moderate … Read more
Suven Life Sciences has secured one product patent from India and one product patent from South Korea corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2029 and 2033 respectively. The granted claims of the patents include the class of selective Alpha4 … Read more
